Transforming the discovery of novel GPCR-targeted therapies
Tectonic is a clinical-stage biotech co-founded by Harvard Medical School scientists, developing therapeutic proteins and antibodies targeting G-Protein Coupled Receptors (GPCRs) using its proprietary GEODe™ platform. Its pipeline addresses significant unmet medical needs including Group 2 Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2025
Apr 2021
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Biopharmaceutical company developing sustained-release hydrogel therapies targeting retinal disea...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
